INTRODUCTION
============

Chronic kidney disease (CKD) is a major public health problem. In Japan, CKD affects 13.3 million adults.^[@r01]^ With the increasing incidence of hypertension and type 2 diabetes and the aging of the Japanese population, the number of individuals with CKD will likely continue to increase. CKD is recognized as an independent risk factor for myocardial infarction and cardiovascular mortality and can result in significant morbidity, mortality, and increased medical costs.^[@r02]^

Obesity is also a major public health issue, and its prevalence has been increasing worldwide. Obesity is associated with the development of many cardiovascular disease (CVD) risk factors, including type 2 diabetes mellitus,^[@r03],[@r04]^ hypertension,^[@r05],[@r06]^ dyslipidemia,^[@r07]^ and CKD.^[@r08]^ Prospective cohort studies have revealed the longitudinal relation between body mass index (BMI) and the risk of moderate CKD. A greater baseline BMI was associated with an increased risk of stage ≥3 CKD in the Physician's Health Study,^[@r09]^ the Hypertension Detection and Follow-Up Program,^[@r10]^ and the Framingham Heart Study.^[@r11]^ Because treatment of long-term CKD is costly, the best approach is to reduce the incidence of stage ≥3 CKD or prevent it entirely. Examining the modifiable risk factors for stage ≥3 CKD, such as obesity, is important because of the public health implications.

A relationship between obesity and the risk of stage ≥3 CKD in Japanese participants has been reported.^[@r12]^ However, not enough information was presented to examine the dose-response relationship between obesity and the risk of CKD (ie obesity was only considered as dichotomous data); consequently, the dose-response relationship in Japanese individuals remains unclear. An examination of the CKD risk using more-detailed BMI categories in a large cohort is warranted. Additionally, no studies have considered the age-specific relationship between BMI and the development of stage ≥3 CKD. Further research on this issue may help officials implement more effective public health and clinical efforts aimed at the primary prevention of CKD. The purpose of our study was to examine the dose-response relationship between BMI and the development of stage ≥3 CKD in a general Japanese population.

METHODS AND PROCEDURES
======================

Study population
----------------

The study population consisted of 194 333 individuals (63 865 men and 130 468 women) aged 40--79 years who were living in Ibaraki Prefecture, Japan. These individuals had participated in community-based annual health checkups in 1993 (as part of the Ibaraki Prefectural Health Study), which were conducted by the local governments in accordance with the Law of Health and Medical Services for the Elderly. The Ibaraki prefectural government collected data from the local governments, and personal information was removed to ensure anonymity. We excluded 18 939 patients (2367 men and 16 572 women) because of incomplete data, 10 075 individuals (4101 men and 5974 women) because of a history of CVD, and 10 491 individuals (3615 men and 6876 women) because of the presence of stage ≥3 CKD and/or ongoing treatment for CKD. We further excluded 48 864 individuals (17 999 men and 30 865 women) who failed to participate in the 1994 survey, thereby ensuring that all of the participants were followed for at least one year.

Ultimately, the study included 105 611 participants (35 738 men and 69 873 women). These participants were followed by annual examinations until a diagnosis of stage ≥3 CKD, withdrawal from the repeated examinations, or the end of 2006, whichever occurred first. The Ibaraki Epidemiology Study Union Ethics Review Committee approved the protocol for this cohort study.

Measurements
------------

Kidney function was assessed using the estimated glomerular filtration rate (eGFR). The eGFR was calculated using the new Japanese abbreviated prediction equation,^[@r13]^ modified from the Modification of Diet in Renal Disease (MDRD) Study,^[@r14]^ as recommended by the Japanese Society of Nephrology: $$\begin{array}{ll}
 & {\text{eGFR}(\text{mL}/\lbrack\text{min} \cdot 1.73m^{2}\rbrack)} \\
 & {\quad = {\lbrack 194 \times (\text{serum~creatinine}\lbrack\text{mg}/\text{dL}\rbrack)\rbrack}^{- 1.094}} \\
 & {\text{\quad\quad} \times {(\text{age})}^{- 0.287} \times 0.739(\text{for~women~only})} \\
\end{array}$$According to Levey et al, stage ≥3 CKD is defined as the presence of kidney damage or an eGFR \<60 mL/min/1.73 m^2^ reported at least twice in successive annual surveys.^[@r15]^

Serum creatinine level was measured using the Jaffe method with an automated analyzer (Hitachi 7350; Hitachi, Tokyo, Japan, or RX-30; Nihon Denshi, Tokyo, Japan) in 1993--2003; in 2004--2006, it was measured using the enzyme method with an automated analyzer (Hitachi 7770; Hitachi). The coefficient of validation for creatinine value was 0.61%. Serum creatinine measurements from 1993--2003 were converted to the value obtained in the enzyme method using the following equation:$$\begin{array}{ll}
 & \text{serum~creatinine~by~enzyme~method~(mg/dL)} \\
 & {\quad = 0.9915 \times \text{serum~creatinine~by~the~Jaffe~method~(mg/dL)}} \\
 & {\text{\quad\quad} - 0.211} \\
\end{array}$$

The serum creatinine values measured using the enzyme method and the serum creatinine values measured using the Jaffe method were then converted to the enzyme method from the same subjects at the same point in time, and the comparability between them was found to be excellent (*r* = 0.99, *P* \< 0.001). Proteinuria was defined as a urinary protein excretion of 1+ or more by dipstick test (Ames Hemacombisticks; Bayer-Sankyo Ltd., Tokyo, Japan).

The patients' height in sock feet and weight in light clothing were measured at baseline. BMI was calculated as the weight in kilograms divided by the height in meters squared (kg/m^2^).

We measured the following cardiovascular risk factors: serum total cholesterol, serum high-density-lipoprotein (HDL) cholesterol, serum triglyceride, plasma glucose, blood pressure, use of medications, cigarette smoking, and typical alcohol intake. Blood samples were drawn into two polyethylene terephthalate tubes from seated participants; one tube contained an accelerator, while the other contained sodium fluoride and ethylenediaminetetraacetic acid. Overnight fasting (≥8 h) was not mandatory. The serum total cholesterol and serum triglyceride levels were measured using the enzyme method with the RX-30 device in 1993--1995, the H7350 device in 1996--2003, and the H7700 device in 2004--2006. The HDL cholesterol levels were measured using the phosphotungstic acid magnesium method with an MTP-32 device (Corona Electric, Ibaraki, Japan) in 1993--1995, the selective inhibition method with the H7350 device in 1996--2003, and the H7700 device in 2004--2006. Dyslipidemia was defined as triglycerides ≥1.7 mmol/L, HDL cholesterol \<1.036 mmol/L, or as the patient being prescribed medication for dyslipidemia treatment.

The blood glucose level was measured using the glucose oxidase electrode method with a GA1140 device (Kyoto Daiichi Kagaku, Kyoto, Japan) in 1993--1996, the enzyme method with a H7170 device (Hitachi) in 1997--2003, and the H7700 device in 1994--2006. The participants were considered diabetic if they had a plasma glucose of ≥6.1 mmol/L in a fasted state or ≥7.8 mmol/L in a non-fasted state, or if they were being treated for diabetes mellitus. The laboratory participated in external standardization and successfully met the criteria for precision accuracy for the measurement of blood samples, as established by the Japan Medical Association, the Japanese Association of Medical Technologists, and the Japan Society of Health Evaluation and Promotion.

Blood pressure was measured on the right arm of seated participants who had rested for more than 5 min; trained observers obtained these measurements using a standard mercury sphygmomanometer in 1993--2004 and an automated sphygmomanometer in 2005--2006. When the systolic blood pressure was \>150 mm Hg or the diastolic blood pressure was \>90 mm Hg, a second measurement was obtained after the subject took several deep breaths. The lower values, which were almost always observed during the second measurement, were used for the analyses. Hypertension was defined as systolic blood pressure ≥140 mm Hg, diastolic blood pressure ≥90 mm Hg, or use of antihypertensive medication. CVD risk factors were defined as hypertension, dyslipidemia, and diabetes.

Lastly, we conducted an interview to ascertain the number of cigarettes smoked per day, the typical weekly alcohol intake (converted to grams of ethanol per day), and the history of CVD and CKD.

Statistical analysis
--------------------

The participants were classified into the following categories with regard to their BMI (kg/m^2^): \<18.5; 18.5--20.9; 21.0--22.9; 23.0--24.9; 25.0--26.9; 27.0--29.9; or ≥30.0. To compare the participants' physical characteristics according to the BMI categories, one-way analysis of variance was used for continuous variables, and a χ^2^-test was used for categorical variables. The Cox proportional hazards regression model was used to calculate hazard ratios (HRs) and the 95% confidence intervals (CIs) of risk of development of stage ≥3 CKD relative to the BMI categories in comparison to the reference group, 21.0--22.9 kg/m^2^. A BMI of 22 kg/m^2^ is commonly set as the optimal body size in Japan.^[@r16]^ The analyses were stratified by sex and age groups (40--59 and 60--79 years old).

We used two multivariate-adjusted models. In model one, covariates included age and the potential confounders of cigarette smoking (never, former, current \[1--19 cigarettes/day or ≥20 cigarettes/day\]) and typical alcohol intake (never, sometimes, everyday \[\<56 g/day or ≥56 g/day\]). In model two, potential mediators were added to model one. Potential mediators included systolic blood pressure, the use of antihypertensive medication (yes or no), triglyceride level (log-transformed), serum total cholesterol, serum HDL cholesterol, the use of lipid medication (yes or no), blood glucose status (normal \[\<6.1 mmol/L in a fasted state or \<7.8 mmol/L in a non-fasted state\], borderline \[6.1--7.0 mmol/L in a fasted state or 7.8--11.1 mmol/L in a non-fasted state\], hyperglycemic \[\>7.0 mmol/L in a fasted state or \>11.1 mmol/L in a non-fasted state\]), the use of diabetes medication (yes or no), and proteinuria (yes or no). A *P* value \<0.05 was regarded as statistically significant. The SAS System for Windows, release 9.3 (SAS Institute Inc., Cary, NC, USA), was used for all analyses.

RESULTS
=======

Sex-stratified baseline characteristics of the cardiovascular risk factors according to our BMI categories are provided in Table [1](#tbl01){ref-type="table"}. All of the factors, except diabetic medication use in men and lipid medication use in men and women, were associated with BMI in both sexes. A higher BMI was linked with a higher eGFR and a higher prevalence of proteinuria in both sexes.

###### Baseline characteristics of participants by BMI categories

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gender and baseline variables         Body mass index, kg/m^2^   *P* for\                                                                                  
                                                                   difference                                                                                
  ------------------------------------- -------------------------- -------------- -------------- -------------- -------------- -------------- -------------- ---------
  Men (*n* = 35 738)                                                                                                                                         

   Number of participants               1570                       6717           9044           9097           5928           2899           483             

   Age, years                           65.0 (8.8)                 62.5 (9.5)     60.8 (9.7)     59.8 (9.7)     59.0 (9.6)     58.9 (9.4)     57.4 (9.4)     \<0.001

   eGFR, mL/(min·1.73 m^2^)             89.9 (18.6)                90.2 (18.4)    88.6 (17.4)    87.1 (17.3)    86.4 (16.8)    85.3 (16.5)    84.4 (16.6)    \<0.001

   Proteinuria, %                       2.2                        1.7            1.4            1.8            2.2            3.7            6.4            \<0.001

   Total cholesterol, mmol/L            4.67 (0.81)                4.75 (0.82)    4.94 (0.85)    5.07 (0.86)    5.17 (0.86)    5.21 (0.86)    5.26 (0.86)    \<0.001

   HDL cholesterol, mmol/L              1.63 (0.43)                1.52 (0.40)    1.41 (0.38)    1.30 (0.34)    1.24 (0.31)    1.18 (0.29)    1.14 (0.28)    \<0.001

   Triacylglycerol, mmol/L              1.06 (0.59)                1.21 (0.71)    1.50 (0.91)    1.78 (1.05)    2.05 (1.22)    2.23 (1.31)    2.32 (1.31)    \<0.001

   Blood glucose, mmol/L                6.41 (2.15)                6.37 (2.09)    6.35 (1.98)    6.39 (2.03)    6.45 (2.01)    6.60 (2.26)    6.70 (2.23)    \<0.001

   Systolic blood pressure, mm Hg       131.4 (18.2)               133.5 (17.7)   135.1 (16.9)   136.9 (16.6)   138.2 (16.2)   140.8 (16.7)   142.6 (16.2)   \<0.001

   Diastolic blood pressure, mm Hg      76.9 (10.6)                78.1 (10.4)    79.7 (10.3)    81.3 (10.3)    82.9 (10.3)    84.6 (10.6)    86.9 (10.9)    \<0.001

   Lipid medication use, %              0.4                        0.7            1.2            1.6            1.5            2.0            2.3            0.289

   Diabetic medication use, %           3.2                        2.6            2.7            3.6            3.7            4.0            3.1            0.361

   Antihypertensive medication use, %   12.5                       14.5           16.6           19.7           22.4           26.5           32.1           \<0.001

   Smoking status, %                                                                                                                                         \<0.001

    Never                               18.1                       18.7           22.3           24.1           24.4           25.1           28.6            

    Former                              22.2                       23.5           27.3           30.3           32.0           33.3           28.8            

    Current                                                                                                                                                  

     \<20 cigarettes/day                26.4                       21.0           16.2           13.8           12.0           10.7           9.7             

     ≥20 cigarettes/day                 33.3                       36.8           34.2           31.9           31.6           31.0           32.9            

   Alcohol intake, %                                                                                                                                         \<0.001

    Never                               44.8                       35.6           31.9           31.1           31.0           33.4           37.7            

    Sometimes                           10.4                       11.1           11.9           13.8           14.6           15.7           14.9            

    Everyday                                                                                                                                                 

     \<56 g/day                         41.1                       47.5           49.5           49.1           47.3           42.9           38.9            

     ≥56 g/day                          3.6                        5.8            6.7            6.1            7.1            8.1            8.5             

  Women (*n* = 69 873)                                                                                                                                       

   Number of participants               2846                       12 052         17 146         17 122         11 559         7229           1919            

   Age, years                           60.4 (10.3)                57.5 (9.8)     57.8 (9.3)     58.5 (8.8)     59.4 (8.6)     59.8 (8.4)     59.0 (8.5)     \<0.001

   eGFR, mL/(min·1.73 m^2^)             94.5 (22.0)                96.1 (22.3)    94.2 (21.1)    93.4 (24.9)    91.8 (20.7)    91.4 (20.4)    91.3 (21.0)    \<0.001

   Proteinuria, %                       0.9                        0.7            0.8            0.9            1.2            1.7            3.3            \<0.001

   Total cholesterol, mmol/L            5.19 (0.88)                5.27 (0.87)    5.39 (0.89)    5.48 (0.89)    5.55 (0.88)    5.60 (0.91)    5.61 (0.92)    \<0.001

   HDL cholesterol, mmol/L              1.72 (0.40)                1.61 (0.38)    1.51 (0.36)    1.43 (0.34)    1.38 (0.33)    1.35 (0.31)    1.33 (0.31)    \<0.001

   Triacylglycerol, mmol/L              1.07 (0.50)                1.23 (0.65)    1.42 (0.79)    1.61 (0.90)    1.77 (0.96)    1.88 (1.04)    1.94 (0.99)    \<0.001

   Blood glucose, mmol/L                5.90 (1.61)                5.79 (1.40)    5.83 (1.40)    5.96 (1.50)    6.04 (1.52)    6.16 (1.71)    6.35 (2.03)    \<0.001

   Systolic blood pressure, mm Hg       126.5 (17.9)               127.2 (17.3)   130.1 (17.0)   132.7 (16.9)   135.4 (16.6)   138.6 (16.8)   141.7 (16.9)   \<0.001

   Diastolic blood pressure, mm Hg      73.5 (10.4)                74.7 (10.3)    76.4 (10.1)    78.3 (10.0)    79.9 (10.0)    82.0 (10.0)    84.1 (10.6)    \<0.001

   Lipid medication use, %              1.9                        2.2            3.2            3.8            4.2            4.6            4.6            0.988

   Diabetic medication use, %           1.3                        1.5            1.5            1.9            2.3            2.7            3.2            \<0.001

   Antihypertensive medication use, %   8.7                        10.4           13.8           19.0           23.9           30.6           38.0           \<0.001

   Smoking status, %                                                                                                                                         \<0.001

    Never                               92.2                       95.1           95.5           95.9           95.7           95.2           93.3            

    Former                              0.5                        0.4            0.6            0.5            0.6            0.7            0.8             

    Current                                                                                                                                                  

     \<20 cigarettes/day                4.9                        3.2            2.7            2.4            2.5            2.7            3.9             

     ≥20 cigarettes/day                 2.3                        1.3            1.1            1.3            1.3            1.5            2.1             

   Alcohol intake, %                                                                                                                                         \<0.001

    Never                               91.3                       90.0           90.0           90.7           90.8           91.7           91.5            

    Sometimes                           4.8                        5.8            6.3            5.7            5.9            5.1            4.8             

    Everyday                                                                                                                                                 

     \<56 g/day                         3.9                        4.1            3.6            3.5            3.2            3.1            3.4             

     ≥56 g/day                          ---                        0.1            0.1            0.1            0.1            0.1            0.3             
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; SD, standard deviation.

Showing mean (SD) for continuous variables: age, fasting and non-fasting blood glucose, systolic and diastolic blood pressure, total cholesterol, HDL cholesterol, and triglycerides.

SI conversion factors: to convert blood glucose values to mmol/L, multiply by 0.055 51; to convert cholesterols values to mmol/L, multiply by 0.025 86; to convert triglycerides values to mmol/L, multiply by 0.011 29.

Of the 105 611 participants (35 738 men and 69 873 women), 19 384 (18.4%) developed stage ≥3 CKD (5978 men and 13 406 women) over a mean follow-up of 5 years (4.9 years for men and 5.1 years for women). Table [2](#tbl02){ref-type="table"} and [Figure](#fig01){ref-type="fig"} show the sex-stratified HRs for the incidence of stage ≥3 CKD according to BMI category. In both sexes, compared to a BMI of 21.0--22.9 kg/m^2^, the age- and potential confounder-adjusted HRs were higher for the higher BMI categories (model 1; *P* for trend \<0.001; Table [2](#tbl02){ref-type="table"}). Further, these results were similar even when adjusted for potential mediators (model 2; [Figure](#fig01){ref-type="fig"}). The HRs of BMI ≥30.0 kg/m^2^ were markedly higher in men and women (HR 1.60, 95% CI 1.24--2.06 and HR 1.41, 95% CI 1.25--1.60, respectively).

![The multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the development of stage ≥3 chronic kidney disease (CKD) in men and women.](je-24-444-g001){#fig01}

###### Sex-specific HRs and 95% CI for stage ≥3 CKD by BMI categories

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Sex and body mass\   Number of\     Number of\     Incidence rates\   Age-adjusted\   95% CI           Multivariate-\    95% CI           *P* for\
  index category\      participants   person-years   per 1000\          HR                               adjusted HR^a^\                    trend
  (kg/m^2^)                                          person-years                                        (model 1)                          
  -------------------- -------------- -------------- ------------------ --------------- ---------------- ----------------- ---------------- ----------
  Men                                                                                                                                       

   \<18.5              1570           7061           20.1               **0.76**        **0.63, 0.90**   **0.73**          **0.69, 0.61**    

   18.5--20.9          6717           33 677         20.1               **0.90**        **0.82, 0.99**   **0.89**          **0.87, 0.81**    

   21.0--22.9          9044           47 022         19.9               1               (ref.)           1                 (ref.)            

   23.0--24.9          9097           46 973         23.1               **1.27**        **1.16, 1.38**   **1.27**          **1.09, 1.17**   \<0.001

   25.0--26.9          5928           30 170         22.9               **1.38**        **1.25, 1.52**   **1.39**          **1.11, 1.26**    

   27.0--29.9          2899           14 091         23.6               **1.48**        **1.31, 1.68**   **1.48**          **1.08, 1.30**    

   ≥30.0               483            2252           28.4               **2.01**        **1.56, 2.59**   **1.98**          **1.24, 1.54**    

  Women                                                                                                                                     

   \<18.5              2846           14 223         19.8               **0.75**        **0.66, 0.85**   **0.74**          **0.72, 0.66**    

   18.5--20.9          12 052         65 680         17.8               **0.86**        **0.80, 0.93**   **0.86**          **0.84, 0.80**    

   21.0--22.9          17 146         94 954         20.1               1               (ref.)           1                 (ref.)            

   23.0--24.9          17 122         92 420         22.0               1.05            0.99, 1.12       1.05              0.95, 0.99       \<0.001

   25.0--26.9          11 559         61 186         24.7               **1.11**        **1.04, 1.19**   1.11              0.96, 1.04        

   27.0--29.9          7229           36 348         27.9               **1.23**        **1.14, 1.33**   **1.23**          **1.01, 1.14**    

   ≥30.0               1919           8760           34.5               **1.66**        **1.47, 1.87**   **1.64**          **1.25, 1.45**    
  ----------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.

^a^Adjusted for age (years), smoking status (never, ex-, current \<20 cigarettes/day, or ≥20 cigarettes/day), and alcohol intake (never, sometimes, \<56 g/day, or ≥56 g/day).

Table [3](#tbl03){ref-type="table"} shows the sex-stratified HRs for stage ≥3 CKD by BMI categories among diabetes-free and CVD risk factor-free patients at baseline. In analyses limited to those free of either diabetes or of any CVD risk factors, the HRs were higher for the higher BMI categories (*P* for trend \<0.001).

###### Sex-specific HRs and 95% CIs for stage ≥3 CKD by BMI categories among diabetes-free and CVD risk factor-free at baseline

  --------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sex and body\                     Number of\   Number of\     Incidence rates\   Age-adjusted\   95% CI           Multivariable\   95% CI           *P* for\
  mass index\                       subjects     person-years   per 1000\          HR                               HR^c^                             trend
  category (kg/m^2^)                                            person-years                                                                          
  --------------------------------- ------------ -------------- ------------------ --------------- ---------------- ---------------- ---------------- ----------
  **Diabetes**^a^**-free**                                                                                                                            

  **Men**                                                                                                                                             

   \<18.5                           1207         5426           19.5               **0.73**        **0.60, 0.90**   **0.80**         **0.65, 0.99**    

   18.5--20.9                       5352         26 978         19.4               **0.89**        **0.79, 0.99**   0.94             0.84, 1.05        

   21.0--22.9                       7247         38 202         19.9               1               (ref.)           1                (ref.)            

   23.0--24.9                       7255         37 952         23.1               **1.27**        **1.15, 1.40**   **1.21**         **1.09, 1.33**   \<0.001

   25.0--26.9                       4601         23 495         23.0               **1.38**        **1.24, 1.55**   **1.26**         **1.12, 1.41**    

   27.0--29.9                       2227         11 013         22.2               **1.44**        **1.25, 1.67**   **1.24**         **1.07, 1.44**    

   \>30.0                           359          1715           29.2               **2.02**        **1.52, 2.69**   **1.64**         **1.23, 2.19**    

  **Women**                                                                                                                                           

   \<18.5                           2492         12 512         19.4               **0.75**        **0.65, 0.86**   **0.80**         **0.70, 0.92**    

   18.5--20.9                       10 818       58 756         17.3               **0.86**        **0.79, 0.93**   **0.89**         **0.82, 0.96**    

   21.0--22.9                       15 336       85 182         19.8               1               (ref.)           1                (ref.)            

   23.0--24.9                       15 086       81 737         21.4               1.03            0.97, 1.11       1.00             0.93, 1.06       \<0.001

   25.0--26.9                       10 024       53 502         24.4               **1.11**        **1.03, 1.19**   1.04             0.96, 1.11        

   27.0--29.9                       6182         31 475         27.2               **1.21**        **1.12, 1.32**   **1.09**         **1.00, 1.18**    

   \>30.0                           1574         7272           33.7               **1.65**        **1.44, 1.89**   **1.41**         **1.23, 1.62**    

  **CVD risk factor**^b^**-free**                                                                                                                     

  **Men**                                                                                                                                             

   \<18.5                           501          2364           11.8               **0.63**        **0.42, 0.95**   **0.64**         **0.42, 0.96**    

   18.5--20.9                       1815         9989           12.0               0.83            0.65, 1.06       0.84             0.65, 1.08        

   21.0--22.9                       1945         10 918         12.4               1               (ref.)           1                (ref.)            

   23.0--24.9                       1528         8402           13.9               **1.29**        **1.01, 1.65**   **1.30**         **1.01, 1.67**   \<0.001

   25.0--26.9                       757          4007           12.5               1.36            0.98, 1.88       1.30             0.93, 1.81        

   27.0--29.9                       232          1121           16.1               **1.85**        **1.13, 3.03**   **1.78**         **1.08, 2.93**    

   \>30.0                           29           109            9.2                2.20            0.31, 15.75      1.94             0.27, 13.92       

  **Women**                                                                                                                                           

   \<18.5                           1304         6802           15.1               0.90            0.72, 1.12       0.92             0.74, 1.15        

   18.5--20.9                       5285         29 349         12.0               0.99            0.86, 1.14       1.01             0.87, 1.16        

   21.0--22.9                       6243         36 399         11.8               1               (ref.)           1                (ref.)            

   23.0--24.9                       4920         27 907         14.0               **1.17**        **1.02, 1.34**   **1.16**         **1.01, 1.33**   \<0.001

   25.0--26.9                       2509         14 196         16.3               **1.27**        **1.08, 1.49**   **1.21**         **1.03, 1.42**    

   27.0--29.9                       1126         5989           19.2               **1.57**        **1.27, 1.92**   **1.47**         **1.2, 1.81**     

   \>30.0                           222          1111           26.1               **2.15**        **1.47, 3.13**   **1.98**         **1.35, 2.89**    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; CVD, cardiovascular disease; HR, hazard ratio.

^a^Diabetes is defined as plasma glucose ≥6.1 mmol/L in a fasted state or ≥7.8 mmol/L in a non-fasted state, or being treated for diabetes mellitus.

^b^Cardiovascular disease risk factors are hypertension, dyslipidemia, and diabetes.

^c^Adjusted for age (years), systolic blood pressure (mm Hg), total cholesterol level (mmol/liter), high-density lipoprotein cholesterol level (mmol/liter), log-transformed triglyceride level (mmol/liter), proteinuria (yes or no), smoking status (never, ex-, current \<20 cigarettes/day, or ≥20 cigarettes/day), and alcohol intake (never, sometimes, \<56 g/day, or ≥56 g/day).

Table [4](#tbl04){ref-type="table"} shows the sex- and age-stratified HRs for the incidence of stage ≥3 CKD by BMI category compared with a BMI of 21.0--22.9 kg/m^2^. In men aged 40--59 years, the multivariable HRs of BMI ≥30.0 kg/m^2^ were significantly higher. In men aged 60--79 years, the multivariable HRs of BMI ≥23.0 kg/m^2^ were significantly higher. In women aged 40--59 years, the multivariable HRs of the overall BMI categories were not significantly associated (*P* for trend = 0.291). In women aged 60--79 years, the multivariable HRs of BMI ≥27.0 kg/m^2^ were significantly higher. In both sexes and age classes, except women aged 40--59 years, a significant dose-response relationship between BMI and the incidence of stage ≥3 CKD was observed.

###### Age and sex-specific HRs and 95% CIs for stage ≥3 CKD by BMI categories

  -----------------------------------------------------------------------------------------------------------------------------------------------------
  Sex, age group, and\   Number of\     Number of\     Incidence rates\   Age-adjusted\   95% CI           Multivariable\   95% CI           *P* for\
  BMI categories\        participants   person-years   per 1000\          HR                               HR^a^                             trend
  (kg/m^2^)                                            person-years                                                                          
  ---------------------- -------------- -------------- ------------------ --------------- ---------------- ---------------- ---------------- ----------
  Men                                                                                                                                        

   Age 40--59 years                                                                                                                          

    \<18.5               298            1373           2.9                0.44            0.16, 1.18       0.47             0.17, 1.28        

    18.5--20.9           1948           10 900         4.3                **0.63**        **0.45, 0.88**   **0.71**         **0.50, 0.99**    

    21.0--22.9           3310           18 194         6.7                1               (ref.)           1                (ref.)            

    23.0--24.9           3762           20 086         9.4                **1.41**        **1.12, 1.77**   1.22             0.97, 1.54       0.001

    25.0--26.9           2676           14 323         8.9                **1.34**        **1.05, 1.72**   1.10             0.85, 1.42        

    27.0--29.9           1384           7130           10.9               **1.57**        **1.18, 2.09**   1.21             0.90, 1.63        

    ≥30.0                264            1241           16.9               **2.59**        **1.63, 4.11**   **1.83**         **1.14, 2.95**    

   Age 60--79 years                                                                                                                          

    \<18.5               1272           5688           24.3               **0.77**        **0.64, 0.92**   0.84             0.70, 1.01        

    18.5--20.9           4769           22 777         27.7               0.93            0.84, 1.03       0.99             0.89, 1.10        

    21.0--22.9           5734           28 828         28.3               1               (ref.)           1                (ref.)            

    23.0--24.9           5335           26 887         33.4               **1.25**        **1.13, 1.37**   **1.18**         **1.07, 1.30**   \<0.001

    25.0--26.9           3252           15 847         35.5               **1.39**        **1.25, 1.55**   **1.26**         **1.13, 1.41**    

    27.0--29.9           1515           6961           36.6               **1.46**        **1.27, 1.68**   **1.22**         **1.06, 1.41**    

    ≥30.0                219            1011           42.5               **1.83**        **1.34, 2.48**   **1.47**         **1.08, 2.01**    

  Women                                                                                                                                      

   Age 40--59 years                                                                                                                          

    \<18.5               1209           6864           6.8                0.91            0.68, 1.23       0.98             0.72, 1.33        

    18.5--20.9           6611           38 770         6.7                0.91            0.78, 1.07       0.96             0.82, 1.12        

    21.0--22.9           9324           56 401         7.7                1               (ref.)           1                (ref.)            

    23.0--24.9           8808           51 514         8.4                1.04            0.91, 1.19       1.00             0.88, 1.15       0.291

    25.0--26.9           5436           31 685         9.2                1.10            0.95, 1.28       1.02             0.87, 1.18        

    27.0--29.9           3219           17 926         9.5                1.17            0.98, 1.39       1.02             0.85, 1.22        

    ≥30.0                928            4778           11.3               **1.46**        **1.10, 1.94**   1.19             0.90, 1.59        

   Age 60--79 years                                                                                                                          

    \<18.5               1637           7359           31.9               **0.75**        **0.65, 0.86**   **0.81**         **0.70, 0.93**    

    18.5--20.9           5441           26 910         33.9               **0.86**        **0.79, 0.93**   **0.89**         **0.82, 0.97**    

    21.0--22.9           7822           38 553         38.3               1               (ref.)           1                (ref.)            

    23.0--24.9           8314           40 906         39.1               1.04            0.97, 1.12       1.00             0.93, 1.07       \<0.001

    25.0--26.9           6123           29 501         41.4               **1.09**        **1.01, 1.18**   1.02             0.95, 1.10        

    27.0--29.9           4010           18 422         45.8               **1.22**        **1.12, 1.33**   **1.10**         **1.00, 1.19**    

    ≥30.0                991            3982           62.3               **1.67**        **1.46, 1.90**   **1.44**         **1.26, 1.65**    
  -----------------------------------------------------------------------------------------------------------------------------------------------------

BMI, body mass index; CI, confidence interval; CKD, chronic kidney disease; HR, hazard ratio.

^a^Adjusted for age (years), smoking status (never, ex-, current \<20 cigarettes/day, or ≥20 cigarettes/day), alcohol intake (never, sometimes, \<56 g/day, or ≥56 g/day), fasting status (yes or no), systolic blood pressure (mm Hg), antihypertensive medication use (yes or no), total cholesterol level (mmol/liter), high-density lipoprotein cholesterol level (mmol/liter), log-transformed triglyceride level (mmol/liter), lipid medication use (yes or no), blood glucose status (normal: \<6.1 mmol/l during fasting or \<7.8 mmol/l during nonfasting; border: 6.1--7.0 mmol/l during fasting or 7.8--11.1 mmol/l during nonfasting; hyperglycemic: 7.0 mmol/l during fasting or 11.1 mmol/l during nonfasting), diabetes medication use (yes or no), and proteinuria (yes or no).

DISCUSSION
==========

To the best of our knowledge, this is the first cohort study to demonstrate a dose-response relationship between obesity and the risk of stage ≥3 CKD in a Japanese population. The dose-response relationship was found in men aged 40--59 and 60--79 years and in women aged 60--79 years. In addition, this relationship was independent of diabetes and other CVD risk factors (ie hypertension and dyslipidemia). We also observed that the risk of stage ≥3 CKD was markedly higher in obese men and women with a BMI ≥30.0 kg/m^2^ than in men and women with a BMI of 21.0--22.9 kg/m^2^, except in women aged 40--59 years.

The significant relationship observed between BMI and the incidence of stage ≥3 CKD in our study was consistent with that observed in previous studies in Caucasian and Asian populations.^[@r11],[@r17],[@r18]^ The Framingham Offspring Study, which included 2585 participants (mean age, 43 years) who were followed from 1978--2001 (mean follow-up, 18.5 years), showed a strong dose-response relationship between baseline BMI and risk of CKD (defined as eGFR using the MDRD Study equation: ≤64.25 mL/\[min·1.73 m^2^\] in men and ≤59.25 mL/\[min·1.73 m^2^\] in women).^[@r11]^ The multivariable odds ratio of CKD was 1.23 (95% CI, 1.08--1.41) per one standard deviation of approximately 4 kg.^[@r11]^ A Japanese community-based study, which followed 100 753 individuals (mean age, 49 years) for 17 years, revealed that a higher BMI at baseline was associated with an increased risk of end-stage renal disease in men but not women.^[@r18]^ The multivariable-adjusted odds ratios of end-stage renal disease were 1.27 (95% CI, 1.21--1.45) in men and 0.95 (95% CI, 0.83--1.09) in women for each 2 kg/m^2^ increment of BMI.^[@r18]^ Although these authors did not examine the association between BMI and the risk of CKD among older adults, their results in middle-aged adults are consistent with our findings.

The association between obesity and stage ≥3 CKD may be mediated through multiple biological mechanisms, including hormonal factors, inflammation, oxidative stress, and endothelial dysfunction.^[@r19],[@r20]^ In obese individuals, the rennin-angiotensin-aldosterone system is commonly activated,^[@r21]^ and it is a well-coordinated hormonal system that regulates adrenal, cardiovascular, and kidney function by controlling the fluid and electrolyte balance. Activation of this system leads to the development of hypertension via the production of angiotensin 2, which causes further damage to the kidneys.^[@r22]^ Estrogen, a sex hormone that is secreted more in premenopausal women compared with men and postmenopausal women, decreases the expression of angiotensin type 1 receptors in the vasculature and kidneys^[@r23]^ and reduces the expression and activity of angiotensin-converting enzymes.^[@r24],[@r25]^ These biological mechanisms may be underlying factors for the significant relationship between obesity and the development of stage ≥3 CKD among middle-aged women in our study.

The strength of our study is that stage ≥3 CKD was defined as an eGFR level \<60 mL/min/1.73 m^2^ reported at more than two successive annual surveys. Further, all of the blood samples were measured by the same laboratory, which was verified using a validated quality control system.^[@r26]^ However, there are several limitations. First, we only examined generalized obesity and not abdominal obesity, because the measurements of central obesity were not available during the baseline examination. Second, potential residual confounders may not have been assessed, such as fat distribution, dietary lifestyle (ie protein and salt intake), and physical activity. Third, detailed information on use of medications such as statins and omega 3-fatty acids was not collected because of the nature of the community-based health checkup.

Obesity was associated with the risk of developing stage ≥3 CKD among men and older women. Compared with participants who had a normal BMI (21.0--22.9 kg/m^2^), those with a BMI ≥30.0 kg/m^2^ had a markedly high risk of developing stage ≥3 CKD. Weight management may be important for preventing CKD in obese men and women.
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